Published in J Neural Transm (Vienna) on December 15, 2010
Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxid Med Cell Longev (2011) 1.26
Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem (2011) 1.16
Iron homeostasis in osteoporosis and its clinical implications. Osteoporos Int (2012) 0.93
The bad, the good, and the ugly about oxidative stress. Oxid Med Cell Longev (2012) 0.91
Oxidative stress in neurodegenerative diseases. Neural Regen Res (2012) 0.90
Estrogen prevents oxidative damage to the mitochondria in Friedreich's ataxia skin fibroblasts. PLoS One (2012) 0.85
Reduction in mitochondrial iron alleviates cardiac damage during injury. EMBO Mol Med (2016) 0.84
Genetic variation in iron metabolism is associated with neuropathic pain and pain severity in HIV-infected patients on antiretroviral therapy. PLoS One (2014) 0.80
Role of iron in neurodegenerative diseases. J Neural Transm (Vienna) (2016) 0.79
Ceruloplasmin deficiency reduces levels of iron and BDNF in the cortex and striatum of young mice and increases their vulnerability to stroke. PLoS One (2011) 0.78
Iron-mediated redox modulation in neural plasticity. Commun Integr Biol (2012) 0.78
Chronic phencyclidine increases synapsin-1 and synaptic adaptation proteins in the medial prefrontal cortex. ISRN Psychiatry (2013) 0.77
Global stress response in a prokaryotic model of DJ-1-associated Parkinsonism. J Bacteriol (2013) 0.77
Astrocyte hepcidin is a key factor in LPS-induced neuronal apoptosis. Cell Death Dis (2017) 0.75
Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science (1996) 11.59
Regulating the fate of mRNA: the control of cellular iron metabolism. Cell (1993) 6.47
Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72
Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet (2006) 4.61
Function and biogenesis of iron-sulphur proteins. Nature (2009) 4.56
Maturation of iron-sulfur proteins in eukaryotes: mechanisms, connected processes, and diseases. Annu Rev Biochem (2008) 4.34
Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet (1997) 4.26
The role of iron in the activation-inactivation of aconitase. J Biol Chem (1983) 3.42
Iron-sulfur cluster biogenesis and human disease. Trends Genet (2008) 3.03
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet (1998) 2.39
DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature (2003) 2.33
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Functions of mitochondrial ISCU and cytosolic ISCU in mammalian iron-sulfur cluster biogenesis and iron homeostasis. Cell Metab (2006) 2.21
Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol (2005) 2.17
The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood (2007) 2.16
The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res (2000) 2.14
Oxidative stress in patients with Friedreich ataxia. Neurology (2000) 2.03
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol (2005) 1.88
Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance. Am J Hum Genet (2008) 1.84
A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem (1997) 1.83
Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J Biol Chem (2004) 1.80
Friedreich ataxia: an overview. J Med Genet (2000) 1.79
Requirements for iron-regulated degradation of the RNA binding protein, iron regulatory protein 2. EMBO J (1995) 1.76
Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet (2000) 1.70
Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum Mol Genet (2005) 1.69
A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem (1989) 1.58
Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J Biol Chem (2001) 1.56
Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci U S A (1999) 1.56
Iron regulates cytoplasmic levels of a novel iron-responsive element-binding protein without aconitase activity. J Biol Chem (1994) 1.56
Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood (2000) 1.54
The biochemistry of heme biosynthesis. Arch Biochem Biophys (2008) 1.53
Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology (2000) 1.51
Mechanisms of iron-sulfur protein maturation in mitochondria, cytosol and nucleus of eukaryotes. Biochim Biophys Acta (2006) 1.50
Friedreich ataxia. Arch Neurol (2008) 1.40
Myopathy with lactic acidosis is linked to chromosome 12q23.3-24.11 and caused by an intron mutation in the ISCU gene resulting in a splicing defect. Hum Mol Genet (2008) 1.40
RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload. Blood (2006) 1.38
The pathogenesis of cell death in Parkinson's disease. Neurology (2006) 1.38
Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology (2007) 1.38
Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts. J Clin Invest (2010) 1.32
Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab (2009) 1.28
Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol (2001) 1.27
Deficiency of skeletal muscle succinate dehydrogenase and aconitase. Pathophysiology of exercise in a novel human muscle oxidative defect. J Clin Invest (1991) 1.26
Frataxin deficiency alters heme pathway transcripts and decreases mitochondrial heme metabolites in mammalian cells. Hum Mol Genet (2005) 1.23
Glutathione in blood of patients with Friedreich's ataxia. Eur J Clin Invest (2001) 1.22
A pool of extramitochondrial frataxin that promotes cell survival. J Biol Chem (2006) 1.19
Molecular pathogenesis of Parkinson's disease. Hum Mol Genet (2005) 1.16
Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain (1999) 1.16
The molecular basis of Friedreich ataxia. Adv Exp Med Biol (2002) 1.14
HEREDITARY METABOLIC MYOPATHY WITH PAROXYSMAL MYOGLOBINURIA DUE TO ABNORMAL GLYCOLYSIS. J Neurol Neurosurg Psychiatry (1964) 1.14
The neuromelanin of human substantia nigra: physiological and pathogenic aspects. Pigment Cell Res (2004) 1.12
Frataxin interacts functionally with mitochondrial electron transport chain proteins. Hum Mol Genet (2005) 1.11
Linkage of cell-mediated immunity to iron metabolism. Immunol Today (1995) 1.11
A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol Dis (2009) 1.11
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10
Association study between iron-related genes polymorphisms and Parkinson's disease. J Neurol (2002) 1.09
Iron regulatory factor--the conductor of cellular iron regulation. Blood Rev (1993) 1.09
Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder. J Med Genet (1985) 1.09
Brain peroxidase and catalase in Parkinson disease. Arch Neurol (1975) 1.07
Frataxin promotes antioxidant defense in a thiol-dependent manner resulting in diminished malignant transformation in vitro. Hum Mol Genet (2002) 1.07
Extra-mitochondrial localisation of frataxin and its association with IscU1 during enterocyte-like differentiation of the human colon adenocarcinoma cell line Caco-2. J Cell Sci (2005) 1.03
A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease. Antioxid Redox Signal (2009) 1.03
Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation. Can J Physiol Pharmacol (2010) 1.01
The neuromelanin of human substantia nigra and its interaction with metals. J Neural Transm (Vienna) (2002) 1.00
Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci (1988) 0.99
Iron-sulphur clusters as genetic regulatory switches: the bifunctional iron regulatory protein-1. FEBS Lett (1996) 0.98
Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal (2010) 0.93
Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms. Neurochem Res (2007) 0.89
Antioxidant enzymes in blood of patients with Friedreich's ataxia. Arch Dis Child (2002) 0.83
A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities. J Med Chem (2007) 0.82
Iron-dependent enzymes in Parkinson's disease. J Neural Transm Suppl (1995) 0.77
A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med (2006) 8.12
Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28
Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology (2013) 2.99
Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One (2010) 2.15
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol (2003) 2.14
Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2011) 2.12
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Reliability of brain CT evaluation by stroke neurologists in telemedicine. Neurology (2012) 1.54
Autonomic function and cerebral autoregulation in patients undergoing carotid endarterectomy. Circ J (2010) 1.45
Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord (2007) 1.41
Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep (2012) 1.36
Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord (2007) 1.35
Adherence to antiparkinson medication in a multicenter European study. Mov Disord (2009) 1.34
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Mitochondrial cytopathies. J Neurol (2003) 1.28
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol (2010) 1.24
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord (2014) 1.23
The stem cell marker prominin-1/CD133 on membrane particles in human cerebrospinal fluid offers novel approaches for studying central nervous system disease. Stem Cells (2007) 1.21
Genes associated with Parkinson syndrome. J Neurol (2008) 1.21
Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord (2004) 1.09
Transdermal rotigotine for the perioperative management of Parkinson's disease. J Neural Transm (Vienna) (2010) 1.08
Different odor tests contribute differently to the evaluation of olfactory loss. Chem Senses (2007) 1.05
Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord (2009) 1.02
Depression and Parkinson's disease. J Neurol (2004) 1.02
Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci (2006) 1.02
Primary skin fibroblasts as a model of Parkinson's disease. Mol Neurobiol (2012) 1.01
Utility of the WHO-Five Well-being Index as a screening tool for depression in Parkinson's disease. Mov Disord (2010) 1.00
Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. J Neurol Sci (2009) 1.00
A longitudinal study of olfactory function in patients with idiopathic Parkinson's disease. J Neurol (2008) 1.00
Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci (2009) 0.99
Biopsies of olfactory epithelium in patients with Parkinson's disease. Mov Disord (2009) 0.99
Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol (2008) 0.97
Olfactory dysfunction as a diagnostic marker for Parkinson's disease. Expert Rev Neurother (2009) 0.95
Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro Oncol (2010) 0.95
Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol (2010) 0.93
Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci (2005) 0.91
Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm (Vienna) (2009) 0.90
Olfactory training in patients with Parkinson's disease. PLoS One (2013) 0.89
Olfactory loss in Parkinson's disease. Parkinsons Dis (2011) 0.89
Improved odor sensitivity in attention-deficit/hyperactivity disorder. Biol Psychiatry (2008) 0.88
Expression and localization of nuclear proteins in autosomal-dominant Emery-Dreifuss muscular dystrophy with LMNA R377H mutation. BMC Cell Biol (2004) 0.88
Utility of measuring vitamin B12 and its active fraction, holotranscobalamin, in neurological vitamin B12 deficiency syndromes. J Neurol (2010) 0.88
Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord (2012) 0.87
Sleep and non-motor symptoms in Parkinson's disease. J Neural Transm (Vienna) (2013) 0.87
Prediction of outcome in neurogenic oropharyngeal dysphagia within 72 hours of acute stroke. J Stroke Cerebrovasc Dis (2011) 0.86
Health-related quality of life in multiple system atrophy and progressive supranuclear palsy. Neurodegener Dis (2011) 0.86
Dementia in idiopathic Parkinson's syndrome. J Neurol (2004) 0.85
Beyond tremor and rigidity: non-motor features of Parkinson's disease. J Neural Transm (Vienna) (2009) 0.85
Cardiovascular autonomic testing in extrapyramidal disorders. J Neurol Sci (2011) 0.84
Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. Mov Disord (2010) 0.84
Autonomic dysfunction in patients with progressive supranuclear palsy. Mov Disord (2008) 0.84
Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis. Atheroscler Suppl (2009) 0.83
Mitochondrial dysfunction in Parkinson's disease--revisited. Neurol Neurochir Pol (2007) 0.83
Extrapyramidal symptoms in Wilson's disease are associated with olfactory dysfunction. Mov Disord (2006) 0.83
Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism Relat Disord (2007) 0.83
Association of sleep apnea with clinically silent microvascular brain tissue changes in acute cerebral ischemia. J Neurol (2013) 0.82
The exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects. J Neurochem (2010) 0.82
Different diagnostic criteria for Parkinson disease: what are the pitfalls? J Neural Transm (Vienna) (2013) 0.82
Static posturography in aging and Parkinson's disease. Front Aging Neurosci (2012) 0.82
Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease. BMC Neurol (2011) 0.82
Neurotoxic mechanisms of 2,9-dimethyl-beta-carbolinium ion in primary dopaminergic culture. J Neurochem (2006) 0.81
Effects of rasagiline on olfactory function in patients with Parkinson’s disease. Mov Disord (2013) 0.81
Switching and combining of dopamine agonists. J Neurol (2004) 0.81
Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report. Mov Disord (2008) 0.81
Chocolate consumption is increased in Parkinson's disease. Results from a self-questionnaire study. J Neurol (2009) 0.81
Whole blood genome-wide expression profiling and network analysis suggest MELAS master regulators. Neurol Res (2011) 0.80
Emergency transfer of acute stroke patients within the East Saxony telemedicine stroke network: a descriptive analysis. Int J Stroke (2013) 0.79
Computed tomographically-controlled injection of botulinum toxin into the longus colli muscle in severe anterocollis. Mov Disord (2004) 0.79
Early versus delayed initiation of pharmacotherapy in Parkinson's disease. Drugs (2014) 0.79
Trigonometric regressive spectral analysis reliably maps dynamic changes in baroreflex sensitivity and autonomic tone: the effect of gender and age. PLoS One (2010) 0.79
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease. Neurology (2013) 0.78
Microcurrent transcutaneous electric nerve stimulation in painful diabetic neuropathy: a randomized placebo-controlled study. Pain Med (2011) 0.78
Olfactory FMRI in patients with Parkinson's disease. Front Integr Neurosci (2010) 0.78
Prefrontal cortex dysfunction and depression in atypical parkinsonian syndromes. Mov Disord (2007) 0.78
Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. Ann Clin Biochem (2013) 0.78
Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J Neural Transm (Vienna) (2010) 0.78
Determination of baroreflex sensitivity during the modified Oxford maneuver by trigonometric regressive spectral analysis. PLoS One (2011) 0.78
[Teaching of psychosomatic medicine and psychotherapy as an element of the Dresden DIPOL-Curriculum -- the PBL-course "Nervous system" and psyche]. Psychother Psychosom Med Psychol (2003) 0.78
Selective hyposmia in Parkinson's disease? J Neurol (2013) 0.78
Early sleep apnea screening on a stroke unit is feasible in patients with acute cerebral ischemia. J Neurol (2012) 0.78
Analysis of HLA class I and II alleles in sporadic inclusion-body myositis. J Neurol (2003) 0.77
Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia - a randomized, double-blind, double-dummy crossover study. Br J Clin Pharmacol (2014) 0.77
Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug? Expert Rev Neurother (2011) 0.77
Metabolic patterns in meningiomas. J Neurooncol (2003) 0.77
Hypoglycemia-induced choreoathetosis associated with hyperintense basal ganglia lesions in T1-weighted brain MRI. Mov Disord (2010) 0.77
[Interdisciplinarity and chronic pain therapy--implementation of a new Interdisciplinary Center at the University Hospital Dresden on the basis of an integrated health care contract]. Z Arztl Fortbild Qualitatssich (2007) 0.76
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord (2007) 0.76
Autonomic dysfunction in different subtypes of multiple system atrophy. Mov Disord (2008) 0.76
Lewy body dementia and Parkinson's disease with dementia. J Neurol (2008) 0.76
Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. Mov Disord (2007) 0.76
Persistent organic personality change as rare psychiatric manifestation of MELAS syndrome. J Neurol (2003) 0.76
LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients. Atherosclerosis (2010) 0.75
Dementia with Lewy bodies. J Neurol Sci (2006) 0.75
Reduced body mass index in Parkinson's disease: contribution of comorbid depression. J Nerv Ment Dis (2013) 0.75
"Atraumatic" Sprotte needle reduces the incidence of post-lumbar puncture headaches. Neurology (2002) 0.75
Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection"). Neurotherapeutics (2015) 0.75
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2005) 0.75
Olfactory function in patients with and without temporal lobe resection. Epilepsy Behav (2012) 0.75
Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease. Int J Neurosci (2011) 0.75